Improving Retinoblastoma Outcomes: The Critical Role of Standardized High-Risk Histopathological Classification

Retinoblastoma (Rb) is the most prevalent eye cancer in children, with around 8,000 new cases annually. A recent multinational study conducted by Dr. Mattan Arazi and Prof. Ido Didi Fabian from Sheba Global Ophthalmology examined the histopathological features of Rb in 1,426 children across 21 centers in 12 countries from 2011 to 2020, focusing on high-risk histopathological features (HRHF), which are specific tumor characteristics that indicate a greater likelihood of cancer spreading and a poorer prognosis, and their impact on treatment outcomes. The study revealed significant discrepancies in HRHF classification among participating centers worldwide. Of the 600 children analyzed, 10.5% who were initially classified as non-HRHF actually met standardized HRHF criteria upon reevaluation. This misclassification corresponds to approximately 30% of all non-adjuvant treated children who developed metastatic spread and/or died, meaning one-third of these children died due to a misclassification! Among the children studied, 349 (58.2%) were from low- and middle-income countries. While the majority (84.2%) received adjuvant chemotherapy, leading to improved survival rates (95.6% recurrence-free at five years), the discrepancies in classification can critically affect treatment outcomes and patient management. This study highlights the urgent need for standardized definitions of HRHF to ensure consistent diagnosis and treatment protocols in retinoblastoma, ultimately aiming to enhance survival rates for children affected by this aggressive cancer. Read the full article